|1.||Comstock, Timothy L: 6 articles (01/2014 - 01/2008)|
|2.||Holland, Edward J: 4 articles (09/2014 - 09/2004)|
|3.||Sheppard, John D: 3 articles (09/2014 - 02/2011)|
|4.||Siou-Mermet, Raphaele: 3 articles (02/2014 - 01/2012)|
|5.||Rajpal, Rajesh K: 3 articles (10/2013 - 06/2011)|
|6.||Erb, Tara: 3 articles (02/2013 - 01/2011)|
|7.||Lane, Stephen S: 2 articles (09/2014 - 02/2013)|
|8.||Slonim, Charles B: 2 articles (09/2014 - 01/2004)|
|9.||Solomon, Kerry D: 2 articles (09/2014 - 01/2002)|
|10.||Pflugfelder, Stephen C: 2 articles (09/2014 - 09/2004)|
02/01/2014 - "A new gel formulation containing loteprednol etabonate (LE), a C-20 ester corticosteroid used to treat ocular inflammation, was developed to provide increased retention on the ocular surface for improved drug delivery to intraocular tissues. "
01/01/2003 - "Loteprednol etabonate, an inactive metabolite soft steroid, has been accepted for the treatment of ophthalmic disorders and is being examined in clinical trials for its effects on airway inflammation. "
11/01/1998 - "Loteprednol Etabonate Post-operative Inflammation Study Group 1."
09/01/1998 - "The Loteprednol Etabonate Postoperative Inflammation Study Group 2."
10/01/2012 - "The available clinical data suggest that loteprednol etabonate is an efficacious and safe corticosteroid for the treatment of postoperative inflammation."
|2.||Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
10/01/1998 - "Data from 2 double-masked placebo-controlled studies indicate that loteprednol etabonate 0.2% (1 drop/eye 4 times daily for 2 weeks) is effective in patients with moderate to severe seasonal allergic conjunctivitis. "
06/01/1997 - "Loteprednol etabonate is generally effective in prophylaxis of seasonal allergic conjunctivitis and has an acceptable safety profile."
04/01/1993 - "Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis."
12/01/1998 - "Furthermore, based upon a dose-response study in this model, 0.2% loteprednol etabonate was selected for further evaluation in environmental seasonal allergic conjunctivitis studies."
12/01/1998 - "Based upon the results of Study 1, we used the CPT model to aid in the selection of a concentration of loteprednol etabonate for subsequent studies in environmental seasonal allergic conjunctivitis. "
10/01/2013 - "Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies."
02/01/2013 - "Patients with anterior chamber cell (ACC) grade 2 or higher after cataract surgery were randomized to loteprednol etabonate 0.5% gel or vehicle 4 times a day for 14 days. "
09/01/1998 - "This study aimed to compare the efficacy and safety of loteprednol etabonate (LE) 0.5% to placebo (vehicle) in controlling the anterior chamber cell and flare reaction in patients undergoing cataract surgery with intraocular lens (IOL) implantation. "
11/01/1998 - "To compare the efficacy and safety of loteprednol etabonate 0.5% with those of a placebo (vehicle) in controlling anterior chamber cell and flare reaction in patients having cataract surgery with intraocular lens (IOL) implantation. "
10/01/2012 - "Randomized controlled studies have demonstrated the clinical efficacy and safety of loteprednol etabonate ophthalmic suspension 0.5 % for the treatment of postoperative inflammation in post-cataract patients with few patients, if any, exhibiting clinically significant increases (≥10 mmHg) in IOP. "
02/01/2013 - "Significant treatment differences for complete resolution of ACC and grade 0 pain favoring loteprednol etabonate were also found on day 15 and day 18. "
02/01/2013 - "On day 8, 30.5% of patients in the loteprednol etabonate group and 16.3% of patients in the vehicle group had complete resolution of ACC, whereas 72.9% and 41.9%, respectively, had grade 0 pain (both P<.001). "
01/01/2014 - "To review comprehensively the available peer-reviewed published articles in the literature on loteprednol suspension, gel, and ointment in the treatment of ocular inflammation and pain following ocular surgery. "
06/01/2013 - "In conclusion, loteprednol etabonate ophthalmic gel 0.5% is an additional formulation option for the short-term treatment of post-operative inflammation and pain in patients who have undergone ocular surgery. "
06/01/2013 - "Relative to vehicle, loteprednol etabonate ophthalmic gel 0.5% effectively reduced postoperative ocular inflammation and ocular pain and had a similar overall tolerability, comfort and safety profile. "
11/01/2003 - "Examination revealed acute bilateral nongranulomatous anterior uveitis that was effectively treated with loteprednol. "
05/01/1999 - "To compare the safety and efficacy of loteprednol etabonate 0.5% ophthalmic suspension with prednisolone acetate 1.0% ophthalmic suspension in reducing the ocular signs and symptoms associated with acute anterior uveitis. "
05/01/1999 - "Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. "
03/01/2000 - "Lotemax (0.5% LE) has been demonstrated as effective in reducing the signs and symptoms of giant papillary conjunctivitis (GPC), acute anterior uveitis and inflammation following cataract extraction with intraocular lens (IOL) implantation. "
|4.||Adrenal Cortex Hormones (Corticosteroids)
|6.||Ketorolac Tromethamine (Acular)
|1.||Intraocular Lenses (Intraocular Lens)
|3.||Hematopoietic Stem Cell Transplantation
|5.||Laser In Situ Keratomileusis (LASIK)